| Beyond cell death: new functions for TNF family cytokines in autoimmunity and tumor immunotherapy F Yi, N Frazzette, AC Cruz, CA Klebanoff, RM Siegel Trends in molecular medicine 24 (7), 642-653, 2018 | 75 | 2018 |
| Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA SS Chandran, J Ma, MG Klatt, F Dündar, C Bandlamudi, P Razavi, ... Nature medicine 28 (5), 946-957, 2022 | 62 | 2022 |
| Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors Y Yin, K Zheng, N Eid, S Howard, JH Jeong, F Yi, J Guo, CM Park, ... Journal of medicinal chemistry 58 (4), 1846-1861, 2015 | 57 | 2015 |
| Discovery of novel small-molecule inhibitors of LIM domain kinase for inhibiting HIV-1 F Yi, J Guo, D Dabbagh, M Spear, S He, K Kehn-Hall, J Fontenot, Y Yin, ... Journal of virology 91 (13), 10.1128/jvi. 02418-16, 2017 | 41 | 2017 |
| Genistein interferes with SDF-1-and HIV-mediated actin dynamics and inhibits HIV infection of resting CD4 T cells J Guo, X Xu, TK Rasheed, A Yoder, D Yu, H Liang, F Yi, T Hawley, T Jin, ... Retrovirology 10, 1-15, 2013 | 35 | 2013 |
| CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit F Yi, T Cohen, N Zimmerman, FA Dundar, P Zumbo, R Eltilib, EJ Brophy, ... bioRxiv, 2024.02. 26.582108, 2024 | 1 | 2024 |
| Persistence but not antitumor efficacy of CAR-engineered lymphocytes is governed by a FAS/FAS ligand auto-regulatory circuit F Yi, T Cohen, P Zumbo, R Eltilib, H Arkin, M Gormally, CS Hackett, ... Cancer Research 84 (6_Supplement), 40-40, 2024 | | 2024 |
| Erasing iatrogenic neoantigens from in vivo CRISPR screens F Yi, CA Klebanoff Immunity 54 (3), 406-408, 2021 | | 2021 |
| The Roles of LIM Kinase (LIMK) Inhibitors in the Regulation of Actin Dynamics During HIV-1 Infection F Yi George Mason University, 2016 | | 2016 |
